Stock Watch: Novartis And Lilly Pour Cold Water On Q1 Earnings
The Second Week Of Earnings Season Took A Bad Turn
Executive Summary
Novartis’s comparatively anemic revenue growth and Lilly’s sales shortfall suggest that hopes for an immediate sector recovery from the pandemic are premature.